Nephrology prior authorization at Centene
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Centene nephrology PA at a glance
Centene reviews nephrology PA submissions against its medical policy library, with rules drawn primarily from KDIGO (Kidney Disease: Improving Global Outcomes) guidelines. Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet — what to send
- CKD diagnosis stage 1-5 with ICD-10
- Most recent eGFR + UACR
- Prior medication history with reason for discontinuation
- Comorbid diabetes, HF, or hypertension status
- Iron studies / hemoglobin if ESA
Common denial patterns to pre-empt
Patterns observed in nephrology across payers, and where Centene's book of business overlaps:
- SGLT-2 inhibitors for CKD: eGFR threshold not met (varies by indication)
- Anemia of CKD: ESA prescribed without iron repletion or above hemoglobin target
- Hyperkalemia binders: K+ threshold not met or alternatives not tried
- Step therapy through ACEi/ARB before sacubitril/valsartan in HFrEF + CKD
- Medicaid step therapy
Appeal angles when Centene denies
- KDIGO guideline citation
- Cardiovascular outcome trial (EMPA-KIDNEY, DAPA-CKD, FIDELIO-DKD) by name
- Albuminuria (UACR) documentation as risk-modifier
- eGFR trajectory documentation
Peer-to-peer prep
- Bring eGFR trend over 6-12 months (not just the latest value)
- Quote the KDIGO recommendation grade
- For SGLT-2: differentiate the diabetic-CKD vs non-diabetic CKD indication
- Document patient education on volume-status changes with SGLT-2
Drug-specific PA criteria at Centene
Deep dives on each drug's PA criteria at Centene:
Frequently asked questions
What documentation does Centene need for nephrology prior authorizations?
Centene's PA packet for nephrology typically includes: CKD diagnosis stage 1-5 with ICD-10; Most recent eGFR + UACR; Prior medication history with reason for discontinuation; Comorbid diabetes, HF, or hypertension status. KDIGO (Kidney Disease: Improving Global Outcomes) guidelines citations strengthen the submission.
What's the turnaround at Centene?
Centene standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Medicare Advantage extension rule under 42 CFR Part 422 may add 14 days. Internal appeal window if denied: 60 days.
Which nephrology drugs does Centene most often PA-restrict?
Top targets in nephrology: empagliflozin, dapagliflozin, evolocumab. Each follows the per-drug step therapy + documentation requirements published in Centene's medical policy library.
How do I prep a peer-to-peer with Centene in nephrology?
Bring eGFR trend over 6-12 months (not just the latest value) Quote the KDIGO recommendation grade Have the policy URL and the patient's chart open before the call.
Generate a Nephrology PA packet
Open ApprovalHelp — generate a nephrology PA packet tailored to Centene's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com